Seizures and Outcome One Year After Neonatal and Childhood Cerebral Sinovenous Thrombosis.


Journal

Pediatric neurology
ISSN: 1873-5150
Titre abrégé: Pediatr Neurol
Pays: United States
ID NLM: 8508183

Informations de publication

Date de publication:
04 2020
Historique:
received: 05 07 2019
revised: 16 08 2019
accepted: 20 08 2019
pubmed: 29 12 2019
medline: 26 3 2021
entrez: 29 12 2019
Statut: ppublish

Résumé

Pediatric cerebral sinovenous thrombosis is a treatable cause of brain injury, acute symptomatic seizures, and remote epilepsy. Our objective was to prospectively study epilepsy and outcomes in neonates and children one year after cerebral sinovenous thrombosis diagnosis. Patients with cerebral sinovenous thrombosis were enrolled prospectively from 21 international sites through the Seizures in Pediatric Stroke Study. Clinical data, including acute symptomatic seizures and cerebral sinovenous thrombosis risk factors, were collected at diagnosis. A neuroradiologist who was unaware of the diagnosis reviewed acute imaging. At one year, outcomes including seizure recurrence, epilepsy diagnosis, antiepileptic drug use, and modified Engel score were collected. Outcomes were assessed using the modified Rankin score and the King's Outcome Scale for Childhood Head Injury. Twenty-four participants with cerebral sinovenous thrombosis were enrolled (67% male, 21% neonates). Headache was the most common presenting symptom in non-neonates (47%, nine of 19). Nine (37.5%) presented with acute symptomatic seizures. Six (25%; 95% confidence interval, 10% to 47%) developed epilepsy by one-year follow-up. No clinical predictors associated with epilepsy were identified. King's Outcome Scale for Childhood Head Injury and modified Rankin scores at one year were favorable in 71%. Half of the patients who developed epilepsy (three of six) did not have infarcts, hemorrhage, or seizures identified during the acute hospitalization. Our study provides a prospective estimate that epilepsy occurs in approximately one-quarter of patients by one year after diagnosis of cerebral sinovenous thrombosis. Later epilepsy can develop in the absence of acute seizures or parenchymal injury associated with the acute presentation.

Sections du résumé

BACKGROUND
Pediatric cerebral sinovenous thrombosis is a treatable cause of brain injury, acute symptomatic seizures, and remote epilepsy. Our objective was to prospectively study epilepsy and outcomes in neonates and children one year after cerebral sinovenous thrombosis diagnosis.
METHODS
Patients with cerebral sinovenous thrombosis were enrolled prospectively from 21 international sites through the Seizures in Pediatric Stroke Study. Clinical data, including acute symptomatic seizures and cerebral sinovenous thrombosis risk factors, were collected at diagnosis. A neuroradiologist who was unaware of the diagnosis reviewed acute imaging. At one year, outcomes including seizure recurrence, epilepsy diagnosis, antiepileptic drug use, and modified Engel score were collected. Outcomes were assessed using the modified Rankin score and the King's Outcome Scale for Childhood Head Injury.
RESULTS
Twenty-four participants with cerebral sinovenous thrombosis were enrolled (67% male, 21% neonates). Headache was the most common presenting symptom in non-neonates (47%, nine of 19). Nine (37.5%) presented with acute symptomatic seizures. Six (25%; 95% confidence interval, 10% to 47%) developed epilepsy by one-year follow-up. No clinical predictors associated with epilepsy were identified. King's Outcome Scale for Childhood Head Injury and modified Rankin scores at one year were favorable in 71%. Half of the patients who developed epilepsy (three of six) did not have infarcts, hemorrhage, or seizures identified during the acute hospitalization.
CONCLUSION
Our study provides a prospective estimate that epilepsy occurs in approximately one-quarter of patients by one year after diagnosis of cerebral sinovenous thrombosis. Later epilepsy can develop in the absence of acute seizures or parenchymal injury associated with the acute presentation.

Identifiants

pubmed: 31882182
pii: S0887-8994(19)30816-1
doi: 10.1016/j.pediatrneurol.2019.08.012
pmc: PMC7071986
mid: NIHMS1544424
pii:
doi:

Substances chimiques

Anticonvulsants 0

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-26

Subventions

Organisme : NINDS NIH HHS
ID : K12 NS001692
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000143
Pays : United States

Investigateurs

Adam Kirton (A)
Abdalla Abdalla (A)
Dimitrios Zafeiriou (D)
Neil Friedman (N)
Tatia Aprasidze (T)
Anneli Kolk (A)
Jennifer Armstrong (J)
Rebecca Ichord (R)
None Amlie-Lefond
Gabrielle deVeber (G)
Gordana Kovacevic (G)
Marta Hernandez Chavez (M)
Mark Mackay (M)
Luigi Titomanlio (L)
Kristin Guilliams (K)
Jorina Elbers (J)
Heather Fullerton (H)
Susan Benedict (S)
Michael Dowling (M)
Lori Jordan (L)
Paola Pergami (P)

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Neurology. 2016 Jun 7;86(23):2179-86
pubmed: 27164703
Int J Stroke. 2018 Oct;13(8):820-823
pubmed: 29956597
Circulation. 2003 Sep 16;108(11):1362-7
pubmed: 12939214
J Pediatr. 2007 Oct;151(4):409-13, 413.e1-2
pubmed: 17889079
Arch Neurol. 2006 Mar;63(3):405-9
pubmed: 16533968
Dev Med Child Neurol. 2017 Jan;59(1):38-44
pubmed: 27422813
Seizure. 2014 Feb;23(2):135-9
pubmed: 24268724
Neurology. 2012 Aug 28;79(9):864-70
pubmed: 22895580
J Pediatr. 2010 May;156(5):704-10, 710.e1-710.e2
pubmed: 20149389
Dev Med Child Neurol. 2010 Dec;52(12):1145-50
pubmed: 20573178
J Child Neurol. 2008 Jan;23(1):26-31
pubmed: 18184940
J Child Neurol. 2011 Sep;26(9):1137-44
pubmed: 21628696
N Engl J Med. 2001 Aug 9;345(6):417-23
pubmed: 11496852
Neurology. 2017 Feb 14;88(7):630-637
pubmed: 28087825
Stroke. 2008 Apr;39(4):1152-8
pubmed: 18309177
Epilepsia. 2005 Apr;46(4):470-2
pubmed: 15816939
Pediatr Neurol. 2008 Sep;39(3):155-61
pubmed: 18725059
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
J Neuroradiol. 2016 Jul;43(4):280-9
pubmed: 26970861
Front Pediatr. 2017 Jul 27;5:163
pubmed: 28798906
J Child Neurol. 2011 Sep;26(9):1111-20
pubmed: 21693652
Thromb Haemost. 2004 Oct;92(4):713-8
pubmed: 15467900
Dev Neurorehabil. 2012;15(3):171-7
pubmed: 22582847
Arch Dis Child. 2015 Feb;100(2):174-9
pubmed: 25288688
Neurosurgery. 2017 Jan 01;80(1):6-15
pubmed: 27654000
Brain. 2005 Mar;128(Pt 3):477-89
pubmed: 15699061
Ann Neurol. 2013 Aug;74(2):249-56
pubmed: 23613472

Auteurs

Aleksandra Mineyko (A)

Section of Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Neurology, Department Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: Aleksandra.mineyko@ahs.ca.

Adam Kirton (A)

Section of Neurology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Section of Neurology, Department Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Lori Billinghurst (L)

Division of Neurology, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, Pennsylvania.

Nana Nino Tatishvili (NN)

Department of Neurosciences, D. Tvildiani Medical University, M. Iashvili Central Children Hospital, Tbilis, Georgia.

Max Wintermark (M)

Neuroimaging and Neurointervention Division, Department of Radiology, Stanford University Hospital, Stanford, California.

Gabrielle deVeber (G)

Neurology Division, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Christine Fox (C)

Department of Neurology, University of California San Francisco, San Francisco, California; Department of Pediatrics, University of California San Francisco, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH